Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice

[1]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[2]  M. Komajda,et al.  Improving outcomes in chronic heart failure. , 2006, Drugs of today.

[3]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[4]  H. Krumholz,et al.  Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. , 2005, American heart journal.

[5]  F. Haaijer-Ruskamp,et al.  Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study , 2005, European Journal of Clinical Pharmacology.

[6]  J. McMurray,et al.  How much responsibility should heart failure nurses take? , 2005, European journal of heart failure.

[7]  L. Luddington,et al.  Success of a multidisciplinary heart failure clinic for initiation and up‐titration of key therapeutic agents , 2005, European journal of heart failure.

[8]  A. Bennett,et al.  Barriers to diagnosing and managing heart failure in primary care , 2005, The Medical journal of Australia.

[9]  I. S. Virk,et al.  Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure , 2005 .

[10]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[11]  P. Conthe,et al.  Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. , 2005, QJM : monthly journal of the Association of Physicians.

[12]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[13]  K. Tamirisa,et al.  Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. , 2004, American heart journal.

[14]  W. Klein,et al.  Austrian survey of treating heart failure—AUSTRIA , 2004, European journal of heart failure.

[15]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[16]  S. Solomon,et al.  Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2004, European heart journal.

[17]  A. Struthers,et al.  Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. , 2004, British journal of clinical pharmacology.

[18]  M. Gheorghiade,et al.  Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. , 2004, The American journal of cardiology.

[19]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[20]  B. Massie,et al.  Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. , 2004, American heart journal.

[21]  T. Lumley,et al.  Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. , 2004, American heart journal.

[22]  Colin Simpson,et al.  National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland , 2004, Heart.

[23]  J. McMurray,et al.  Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[24]  H. Krumholz,et al.  National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction , 2004, Circulation.

[25]  J. McMurray,et al.  Treatment of heart failure with spironolactone--trial and tribulations. , 2004, The New England journal of medicine.

[26]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[27]  J. Korewicki,et al.  A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns. , 2004, International journal of cardiology.

[28]  P. Armstrong,et al.  The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. , 2004, Archives of internal medicine.

[29]  P. Armstrong,et al.  The Use of -Blockers in a Tertiary Care Heart Failure Clinic , 2004 .

[30]  Mosterd Wl,et al.  [Guideline 'Chronic heart failure']. , 2004 .

[31]  G. Peterson,et al.  Undertreatment of congestive heart failure in an Australian setting , 2004, Journal of clinical pharmacy and therapeutics.

[32]  D. Atar,et al.  Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study , 2003, BMJ : British Medical Journal.

[33]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. , 2003, Journal of the American College of Cardiology.

[34]  A. Mangoni,et al.  Determinants of failure to prescribe target doses of angiotensin‐converting enzyme inhibitors for heart failure , 2003, European journal of heart failure.

[35]  L. Tavazzi,et al.  Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds--the TEMISTOCLE study. , 2003, American heart journal.

[36]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[37]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[38]  D. Webb,et al.  Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non‐cardiologist physicians , 2003, European journal of heart failure.

[39]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[40]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[41]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[42]  Paul A. Heidenreich,et al.  Improving Guideline Adherence: A Randomized Trial Evaluating Strategies to Increase &bgr;-Blocker Use in Heart Failure , 2003, Circulation.

[43]  M. Sturkenboom,et al.  Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000 , 2003, Pharmacoepidemiology and drug safety.

[44]  F. Rutten,et al.  Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every‐day practice , 2003, European journal of heart failure.

[45]  L. Levin,et al.  Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. , 2003, European heart journal.

[46]  S. Yusuf,et al.  The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. , 2003, The Canadian journal of cardiology.

[47]  L. Tavazzi,et al.  Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience , 2003, Heart.

[48]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[49]  N. Hollenberg,et al.  Literature alert , 2002 .

[50]  N. Freemantle,et al.  Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey , 2002, The Lancet.

[51]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[52]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[53]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[54]  I. Piña,et al.  Practical recommendations for the use of ACE inhibitors, beta‐blockers and spironolactone in heart failure: putting guidelines into practice , 2001, European journal of heart failure.

[55]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[56]  H. Krum.  Guidelines for management of patients with chronic heart failure in Australia , 2001, The Medical journal of Australia.

[57]  A. Tonkin,et al.  Chronic heart failure in Australian general practice: The Cardiac Awareness Survey and Evaluation (CASE) Study , 2001, The Medical journal of Australia.

[58]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[59]  T. Allan,et al.  European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). , 2000, European heart journal.

[60]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[61]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[62]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[63]  D. Tepper.  Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). , 1999, Congestive heart failure.

[64]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[65]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[66]  J. McMurray.  Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? , 1998, European heart journal.

[67]  J. Eisenberg,et al.  Views from funding agencies. Agency for Health Care Policy and Research. , 1998, Medical care.

[68]  B. Psaty,et al.  Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. , 1998, Archives of internal medicine.

[69]  S. Reis,et al.  Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. , 1997, Journal of the American College of Cardiology.

[70]  A. Cowley,et al.  Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? , 1997, International journal of cardiology.

[71]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[72]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[73]  E. Philbin,et al.  Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.

[74]  J. McMurray.  Concise Guide to the Management of Heart Failure - World Health Organization/Council on Geriatric Cardiology Task Force on Heart Failure Education. , 1996, The American journal of geriatric cardiology.

[75]  F. Mair,et al.  Prevalence, aetiology and management of heart failure in general practice. , 1996, The British journal of general practice : the journal of the Royal College of General Practitioners.

[76]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[77]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[78]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[79]  M. Whitcomb.  Why we must teach evidence-based medicine. , 2005, Academic medicine : journal of the Association of American Medical Colleges.

[80]  B. Fagerberg,et al.  Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial. , 2003, Heart & lung : the journal of critical care.

[81]  L. Tavazzi,et al.  Beta blockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience , 2003 .

[82]  N. Freemantle,et al.  Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. , 2003, European journal of heart failure.

[83]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[84]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[85]  L. Erhardt,et al.  Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure , 1999, PharmacoEconomics.

[86]  New Zealand guidelines for the management of chronic heart failure. The National Heart Foundation of New Zealand Cardiac Society of Australia and New Zealand and the Royal New Zealand College of General Practitioners Working Party. , 1997, The New Zealand medical journal.

[87]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[88]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.